QUANTIFY RESEARCH is a global partner to the pharmaceutical industry in close partnership with academia, patients, public institutions & clinical experts.
Real-world evidence & analytics
Quantify is the leading provider of RWE generated from the world-renouned Nordic data. Through our local presence, expert staff, institutional know-how and more than 10 years’ hands-on experience with the Nordic data, we offer an unparalleled ability to advise and execute Nordic RWE studies with local and global applications. Quantify has a successful track record of advising clients on securing Nordic ethical approval, data access, and optimizing analysis for commercial or regulatory purposes. We also offer RWE services in the EU, UK, and US.
Modelling, Access & Strategy
Quantify is a global provider of health economic evidence and a specialist provider of Nordic market access services including economic models, reimbursement dossiers, and strategic advice. Our experience and expertise ensures an optimized, streamlined market access process across the Nordics. For non-technical stakeholders, Quantify also develops value tools and visualisation dashboards to enhance communication. Our expert staff include ex-payers, ex-pharma, modelling experts, and experienced project managers.
Evidence review & synthesis
Quantify has long standing experience reviewing, interpreting and communicating evidence as part of targeted or systematic literature reviews (SLR). Our team ensures these activities are done systematically, with a focus on usability, to support knowledge management and commercialization activities. QUANTIFY is experienced in summarizing the results of this work through meta-analyses and narrative reviews. Our team consists of 50% PhDs and integrated AI solutions to provide our clients with the very best services.
Press
New publication on the effects of intensity and adherence to lipid-lowering treatment
Quantify’s Alexander Rieem Dun and Jonas Banefelt are co-authors on a recent publication on the effects of intensity and adherence to lipid-lowering treatment on the risk of cardiovascular events in patients with a recent myocardial infarction. Using Swedish national registers, the study finds that higher intensity and adherence is associated with significantly lower risk of major cardiosvascular events, consistent with findings […]
Dr. Béranger Lueza joins Quantify as Director!
We are excited to introduce our new Director Dr. Béranger Lueza who joined our international Modelling, Access and Strategy unit this week. Béranger is based in Stockholm and has more than 11 years of experience in Health Economics and Outcomes Research and Market Access from consultancy and academia. “We are very pleased and extremely happy that Béranger decided to […]
Systematic literature review of pediatric PCV recommendations in 31 European countries
Do you want to know more about the evidence behind pediatric pneumococcal conjugate vaccine (PCV) recommendations in Europe? Linked below is a recent publication, co-authored by Quantify’s Hanna Fues Wahl, that summarizes the findings from a systematic literature review of pediatric PCV recommendations in 31 European countries.
Click below to learn which type of evidence National Immunization Technical Advisory Groups (NITAGs) and HTA agencies consider when evaluating pediatric PCV national immunization […]
The increasing importance of real-world data
Earlier this week the U.S. Food and Drug Administration (FDA) granted accelerated approval to Vijoice® (alpelisib) based primarily on real-world evidence (RWE). The decision reflects the increasing importance of real-world data (RWD) for regulatory decision making, alongside recent guidance from the FDA and EMA.
As the leading provider of Nordic RWE studies, with more than 200 executed projects involving RWD, […]